30 April 2014AmericasStephanie Pilkington

Protecting biomarkers and personalised/stratified medicine

Interest in the promise of biomarkers and personalised/stratified medicine is building. In the UK, for example, the government announced a Diagnostics for Stratified Medicine Catapult centre in August 2013, and partners including the Technology Strategy Board and the Medical Research Council have committed to spend more than £200 million ($336 million) over a five-year period to promote the development of stratified medicine, providing the tools, processes and systems for identifying the right therapy for the right patient, at the right time and at the right dose.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer’s US Paxlovid patent fight turns on a single error

25 June 2026 The Federal Circuit has brought Paxloid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.